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Reduced cerebral blood flow and
impaired visual–spatial function in
proximal myotonic myopathy
G. Meola, MD; V. Sansone, MD; D. Perani, MD; A. Colleluori, MD; S. Cappa, MD; M. Cotelli, PhD;
F. Fazio, MD; C.A. Thornton, MD; and R.T. Moxley, MD
Article abstract—Objective: To compare brain involvement in myotonic dystrophy (DM) with that of proximal myotonic
myopathy (PROMM). Background: PROMM is a multisystem disease with many features in common with DM. Methods:
Twenty patients with DM (CTG@500–700#), 20 patients with PROMM, and 20 normal control subjects were studied.
Neuropsychological testing was performed in 12 patients with PROMM and in 18 patients with DM; brain MRI was
performed in 17 of 20 PROMM patients and 15 of 20 DM patients. Ten patients with PROMM and 11 patients with DM
were subjected to H2
15O PET. Results: Two-thirds of the patients with PROMM and one-half of those with DM were
impaired on visual–spatial recall, whereas one-third of the patients with PROMM and less than half of those with DM
showed an impairment in visual–spatial construction. Brain MRI was normal, or showed only nonspecific white matter
abnormalities in both PROMM and DM patients. PET studies in PROMM patients showed a bilateral decrease in regional
cerebral blood flow (rCBF) of the orbitofrontal and medial frontal cortex, whereas DM patients had more widespread
hypoperfusion that extended to the dorsolateral frontal cortex and subcortical regions. Conclusions: Impaired visual–
spatial function may be present in proximal myotonic myopathy. This correlates best with a reduction in regional cerebral
blood flow observed in H2
15O PET brain scans rather than with specific structural abnormalities observed on brain MRI.
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Proximal myotonic myopathy (PROMM) and myo-
tonic dystrophy (DM) both involve multiple organ
systems, including the brain.1-9 Hypersomnia
(10%),1,3,10 apathy (5%),3,10 grand mal seizures
(5%),3,10 and mental retardation (5%)3 have all been
noted in PROMM. Hund et al.10 observed diffuse,
confluent lesions in white matter on brain MRI in six
patients with PROMM in whom no symptoms or
signs of mental disorder were present. Three of six of
these patients had strokelike episodes. The changes
on MRI resemble those described in cerebral autoso-
mal dominant arteriopathy with subcortical infarcts
and leukoencephalopathy,11 and the authors sug-
gested that these abnormalities are a feature of
PROMM. In contrast to these findings, Meola et al.4
reported normal brain MRI findings in four patients
with PROMM. Only one patient, a 70-year-old
woman with hypertension, had an abnormal MRI,
which showed nonspecific white matter lesions.
Common symptoms of mental aberration in DM
include apathy, indifference, and lack of motivation
even in patients with mild weakness. A suspicious,
paranoid, or frankly hostile personality is common.
Neuropsychological test results have demonstrated
personality disorders,12 dementia,13-15 mental re-
tardation,13-15 and depression13 in patients with
adult-onset DM. Prominent structural changes in
the brain are infrequent, but some patients with DM
have white matter hyperintense lesions in the ante-
rior portions of the temporal lobes.16,17 Generalized
atrophy has also been observed.14 The relatively few
neuropathologic studies available have shown a dif-
fuse loss of myelin in the deep white matter of the
brain corresponding to the white matter hyperintense
lesions observed on the brain scans.15,18 Pathologic tau
proteins have been found in the hippocampus, the en-
torhinal cortex, and in most of the temporal areas, and
the amount of tau protein was higher in a more se-
verely affected patient.19 A possible relationship be-
tween the decrease of catecholaminergic neurons in the
medullary reticular formation and the presence of alve-
olar hypoventilation has also been suggested.20
From the Department of Neurology (Drs. Meola and Sansone) and Institute of Neuroscience and Bioimaging National Research Council (Drs. Perani,
Colleluori, and Fazio), H. San Raffaele, University of Milan, Italy; the Neurological Department, University of Brescia, and Instituto di Ricovero E Cura A
Carattere Scientifico, S. Giovanni di Dio (Drs. Cappa and Cotelli), Brescia, Italy; and Department of Neurology (Drs. Thornton and Moxley), University of
Rochester, NY.
Supported by the University of Milan, Italy, MURST 40% and 60% (G.M.); the National Council of Research, Italy (D.P.); Muscular Dystrophy Association
(C.T., R.T.M.); General Clinical Research Center–NIH 5M01RR0044 (C.T., R.T.M.), R03 AG14502-01 (C.T., R.T.M.), and R01 AR44069-01A1 (C.T., R.T.M.);
Paul Beeson Physician, Faculty, Scholars in Aging Research Program (C.T.); the Saunders Foundation (C.T., R.T.M.); and the Wayne C. Gorrell Jr. Molecular
Biology Laboratory (C.T., R.T.M.).
Presented in part at the 50th annual meeting of the American Academy of Neurology; Minneapolis, MN; April 1998.
Received July 22, 1998. Accepted in final form April 17, 1999.
Address correspondence and reprint requests to Dr. Giovanni Meola, Department of Neurology, University of Milan, San Donato Hospital, V. Morandi, 30,
20097–San Donato Milanese, Milan, Italy.
1042 Copyright © 1999 by the American Academy of Neurology
To determine whether PROMM patients have
brain alterations similar to those found in patients
with DM we performed neuropsychological testing,
brain MRI, and H2
15O PET.
Methods. Selection of patients. We studied 20 patients
with PROMM from 6 unrelated families (2 from Italy and 4
from the United States; age range, 18 to 73 years; mean
age, 50 years; 11 women and 9 men). In all families at
least one affected person was tested for and did not show
an expanded CTG repeat in the DM gene on chromosome
19. In family 1, which has been described previously,4 link-
age to chromosomes 7 and 17 in addition to chromosome 19
was excluded. In this family and in families 3 and 6, link-
age to chromosome 3q was also excluded.21,22 The remain-
ing families were uninformative for linkage, but CTG
repeat size in the DM gene was normal in the affected
family members. Patient 2 was adopted, so there is no
available information on the family pedigree. However,
given the presence of proximal weakness, electromyo-
graphic myotonia, and early-onset cataracts in the pres-
ence of a normal-size CTG repeat in the DM gene, a
diagnosis of PROMM was made. Additional supportive
findings were the presence of preserved tendon reflexes in
the affected limbs and calf hypertrophy. Twenty DM pa-
tients (CTG@500–700#) (age range, 24 to 68 years; mean age,
43 years; 10 women and 10 men) from 13 unrelated fami-
lies from northern Italy were also studied. Comparable
neuropsychological tests and neuroimaging procedures
were performed in both the Italian and the US patients.
Seventeen of the 20 patients with PROMM and 18 of
the 20 DM patients were ambulatory. It was possible to
perform neuropsychological testing in 12 of 20 patients
with PROMM and in 18 of 20 patients with DM. MRI
evaluation was possible in 17 of 20 PROMM patients and
in 15 of 20 DM patients. H2
15O PET scanning of the brain
occurred in 10 of 20 PROMM patients and 11 of 20 DM
patients. Tables 1 and 2 summarize the clinical and labo-
ratory findings in the patients with PROMM and DM.
Neuropsychological procedures. Neuropsychological
testing was administered by an experienced examiner in a
quiet environment in the hospital or at the patient’s home.
Approximately 60 to 90 minutes were needed to adminis-
ter the battery of tests required. It included a screening
test for dementia (Mini-Mental State Examination
@MMSE#) and tests of nonverbal reasoning (Raven’s colored
matrices), conceptual abilities (Weigl’s sorting test), audi-
tory language comprehension (Token test), verbal fluency
Table 1 Clinical and laboratory data of muscle and brain involvement in our patients with proximal myotonic myopathy
Family no.
and patient no. Age, y/sex
MRC grade*
Onset of
muscle
symptoms,
decade
Onset of brain
symptoms,
decade GCA† FCA† WMHL†Proximal Distal
Family 1 III-1 59/F 41 5 3 5 1 0 0
III-7† 73/F 3 4 3 6 0 0 1
III-8‡ 68/M 3 5 — 2 1 2 0
III-14 65/M 41 5 4 — 0 0 0
IV-2 22/F 5 5 1 — 0 0 0
IV-3 37/F 2 4 2 — 0 0 0
IV-5 34/F 41 5 3 2 0 0 0
IV-7 43/M 52 5 2 — 0 0 0
IV-14 44/F 41 5 3 3 ND ND ND
V-2 18/M 41 5 — 1 1 0 0
Family 2 Patient 2 45/M 41 5 4 — 0 0 0
Family 3 II-1 67/F 4 41 1 3 0 0 1
III-7 39/F 4 5 1 2 0 0 0
Family 4 II-1 70/M 4 41 4 5 2 0 1
III-1 36/F 4 5 2 — 0 0 0
Family 5 I-1 67/M 4 5 2 2 ND ND ND
II-1 47/M 41 5 2 — ND ND ND
II-2 52/M 4 5 2 4 0 1 0
Family 6 II-1 55/F 4 5 3 — 0 0 0
II-3 50/F 4 5 3 — 0 0 1
* Medical Research Council (MRC) grading from 0 to 5 according to the MRC (Aids to the Examination of the Peripheral Nervous Sys-
tem. Memorandum 45—Pendragon House, London, 1976).
† See text for details on grading for general cerebral atrophy (GCA), focal cerebral atrophy (FCA), and white matter hyperintense
lesions (WMHL).
‡ Patient not ambulatory.
— 5 no symptoms; ND 5 not done.
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with phonemic and semantic cues, verbal and spatial
short-term memory (digit span and Corsi block tapping
span), memory for prose (logical memory test), spatial
learning (Corsi supraspan learning), constructional abili-
ties and visual spatial recall (Rey’s complex figure), and a
self-administered depression rating scale (Cognitive Be-
havioral Assessment 2.0 depression scale [Bertolotti G,
Michielin P, Sanavio E, Simonetti G, Vidotto G, Zotti AM;
Organizzazioni Speciali, Firenze, 1986]). The tests were
administered and scored according to published proce-
dures.23,24 Data were compared with 20 age-, gender-, and
education-matched control subjects. Not all patients were
able to perform the full battery of tests. A few refused the
testing and a few had severe distal weakness that made
holding a pen impossible. The results of the neuropsycho-
logical testing in Patient III-8, from family 1 were not
included in the statistical analysis because of his history of
psychiatric disorders and the long-standing use of neuro-
leptic drugs. A review of his medical records suggested a
diagnosis of schizophrenia, superimposed on delayed men-
tal development, which was further complicated by a prob-
able vascular dementia. The data from Patient V-2 from
family 1 was also not included in the overall analysis be-
cause of the long-standing use of antiepileptic drugs and
the patient’s history of delayed mental development. His
father refused to permit PET scanning and also refused
the procedure for himself.
Neuropsychological performance was analyzed by direct
comparison of the raw test scores among the three groups
using one-way analysis of variance. Because of the multi-
ple comparisons, the Bonferroni-corrected significance
threshold was set at 0.0042. Furthermore, to identify the
number of patients who could be considered cognitively
impaired, the scores were corrected for age, education, and
gender using normative data from a large sample of con-
trol subjects (.300). A score in the pathologic range in two
or more tests was considered a criterion for cognitive im-
pairment. The number of patients fulfilling this criterion
in each group was compared by means of a contingency
table (chi-square statistics).
To assess the possible effect of age on neuropsychologi-
cal performance, the age of the cognitively impaired DM
patients was compared with the unimpaired group (the
presence of only two impaired subjects among the PROMM
patients prevented the possibility of a statistical compari-
son) using the Mann–Whitney U test.
Magnetic resonance imaging. MRI was performed with
a scanner operating at a field strength of 1.5 T, and in-
Table 2 Clinical and laboratory data of muscle and brain involvement in our patients with myotonic dystrophy
Patient no.
Age, y/sex/
CTG range
MRC grade*
Onset of
muscle
symptoms,
decade
Onset of brain
symptoms,
decade GCA† FCA† WMHL†Proximal Distal
1‡ 67/M/E2 2 3 5 6 ND ND ND
2‡ 68/F/E2 2 2 3 4 2 0 0
3 28/M/E2 5 4 1 — 1 2 0
4 60/F/E2 3 4 1 4 ND ND ND
5 53/F/E2 3 4 2 4 0 1 2
6 48/F/E2 41 4 2 — 0 0 0
7 62/M/E2 41 4 4 — 2 0 1
8 27/M/E2 5 4 2 — 0 0 0
9 35/M/E2 5 4 2 — 0 0 1
10 24/M/E2 5 4 2 — 0 0 0
11 55/F/E2 5 4 2 — ND ND ND
12 49/F/E2 5 4 3 — 0 1 2
13 38/M/E2 5 41 2 — ND ND ND
14 27/M/E2 5 41 1 — 0 0 0
15 51/F/E2 5 41 3 — 0 0 0
16 40/F/E1 5 41 2 — 0 0 2
17 31/F/E2 4 3 2 — 1 0 1
18 32/F/E2 4 3 2 2 ND ND ND
19 26/M/E2 5 4 2 — 0 0 1
20 33/M/E2 5 4 2 — 1 1 1
* Medical Research Council (MRC) grading from 0 to 5 according to the MRC (Aids to the Examination of the Peripheral Nervous Sys-
tem. Memorandum 45—Pendragon House, London, 1976).
† See text for details on grading for general cerebral atrophy (GCA), focal cerebral atrophy (FCA), and white matter hyperintense
lesions (WMHL).
‡ Patient is not ambulatory.
— 5 no symptoms; ND 5 not done.
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cluded spin-echo pulse sequences in T1-, proton density-,
and T2-weighted imaging. For all scans, section thickness
was 5 mm. All MRI studies were evaluated by a neuroradi-
ologist without knowledge of the clinical status of the pa-
tient. Seventeen patients with PROMM underwent MRI
(three patients refused the procedure). MR images were
obtained for 15 of 20 patients with DM. The remaining five
DM patients were unable to undergo this procedure be-
cause of cardiac pacemakers. By mutual agreement be-
tween the neuroradiologist and neurologist, our evaluation
of the findings on MRI followed the methods of Huber et
al.13 with slight modification. The grading is described in
the following paragraphs.
General cerebral atrophy (GCA). GCA was evaluated
relative to age rather than on an absolute scale. Atrophy
was rated on a scale of 0 to 3, with higher numbers indic-
ative of increasing severity. A score of 0 represented
normal-appearing ventricles and cisterns relative to age,
and no parenchymal atrophy with widening of sulci.
Higher numbers indicated varying degrees of increasing
ventricular and cisternal spaces.
Focal cerebral atrophy (FCA). FCA was rated using
the same scale as that used for GCA, but the rating was
made with respect to a specific region of the brain, such as
when a particular lobe (e.g., temporal) was judged to be
smaller or more atrophic than expected for the patient’s
age (sulci more widened and increased in number).
White matter hyperintense lesions (WMHL). Focal
white matter disease was judged by both the size and
confluency of these lesions: 0, no lesions; 1, a few bilateral
hyperintense lacunae; 2, lesions . 2 cm; and 3, bilateral
lesions . 2 cm, usually confluent.
MRI results were compared with MR images obtained
by members of the neuroradiology department in Italy
from 20 individuals who undertook the examination for
different diagnostic purposes: 11 for transient tingling in
the hands; 4 for persistent headache; 2 for transient, non-
specific speech problems; and 3 for occasional dizziness
and gait disturbances. No GCA, FCA, or WMHL were
present in these subjects.
Data for each individual patient are presented in table
1 for PROMM and in table 2 for DM.
PET acquisition procedures. Eight patients with
PROMM and 11 patients with DM from Italy were studied
by H2
15O PET in a resting state. Two additional patients
with PROMM from the United States had SPECT regional
cerebral blood flow (rCBF) studies of the brain. The PET
tomograph used was GE-Advance (General Electric Medi-
cal System, Milwaukee, WI). The system consists of 18
rings of bismuth germanate, which allows 35 transaxial
images with a slice thickness of 4.25 mm covering an axial
field of view of 15.2 cm. Transmission data were acquired
using a pair of rotating pin sources filled with 68Ge (10
mCi per pin). Image reconstruction was performed with a
filtered back-projection algorithm on a 128 3 128 matrix
with a pixel size of 1.9 mm. rCBF was measured by record-
ing the distribution of radioactivity following an IV bolus
injection of 7 to 8 mCi H2
15O through a forearm cannula. The
integrated counts collected for 70 seconds, starting 20 sec-
onds after injection time, were used as an index of rCBF.
PET data analysis. Reconstructed images of H2
15O
PET were transferred to a dedicated workstation for image
processing (SUN-SPARC 2, Sun Microsystems, Palo Alto,
CA). The data were analyzed with Statistical Parametric
Mapping 1996 (using software from the Wellcome Depart-
ment of Cognitive Neurology, London, UK) implemented in
Matlab version 4.2 (Mathworks Inc., Sherborn, MA).25
PET images were transformed into a stereotactic
space.26 This normalizing spatial conformation matches
each scan to a reference or template image that already
conforms to the standard space.
After specifying the appropriate design matrix, group,
subject, and covariate effects were estimated according to
the general linear model at each and every voxel.25 We
applied analysis of covariance,26 in which the design ma-
trix included global activity and age as confounding covari-
ates. To test the hypothesis about regionally specific
group-versus-group effects, the estimates were compared
using linear contrasts. The resulting set of voxel values for
each contrast constitute a statistical parametric map
(SPM) of the t statistic SPM. In this particular implemen-
tation of the general linear model, the t statistic is, effec-
tively, the rCBF difference between the mean rCBF of the
control group and the rCBF of the patient group under
investigation, divided by the error estimated with the con-
trol group data (after correcting for age and global effect).
The SPMs were transformed to the unit normal distribu-
tion (SPM Z) and thresholded at 3.09 (or corrected at p 5
0.001). The resulting foci were then characterized in terms
of spatial extent (k) and peak heights (u).27
Results. Mental status. The presence of cognitive and
behavioral disorders was determined on the basis of a clin-
ical interview with patients and relatives. A diagnosis of
depression (family 3, Patients II-1 and III-7) and of demen-
tia (family 1, Patients III-8 and V-2; family 4, Patient II-1;
and family 5, Patient II-2) according to criteria in the
Diagnostic and Statistical Manual of Mental Disorders,
4th edition (DSM-IV)28 was made in 6 of 20 patients with
PROMM. In Patient III-8 from family 1, clinical signs and
symptoms of mental retardation began at 14 years of age.
His first admission to a psychiatric hospital was at 27
years of age. He was diagnosed at the time as having
paranoid schizophrenia and oligophrenia. At 65 he had a
stroke with residual mild left hemiparesis. Within 2
months he was diagnosed as having dementia of uncertain
cause. He is currently in a psychiatric hospital. Patient V-2
from family 1 had generalized seizures at 3 years of age,
after normal delivery and birth. At 4 years of age, mental
delay became apparent and seemed to be related to uncon-
trolled seizures. Performance at school was poor. At the
time of this report, the patient is unemployed. A diagnosis
of dementia was made in two other patients. Memory diffi-
culty was the initial symptom in Patient II-1 from family 4
who complained of depression and cognitive impairment.
His cognitive deficits had progressed to the point that a
diagnosis of an Alzheimer’s type of dementia was made.
His 36-year-old daughter complains of mood swings and
often feels depressed, but she is able to continue her every-
day activity. Patient II-2 from family 5 is currently unem-
ployed and is on disability for his disorder. He is currently
complaining of problems with memory, language, atten-
tion, concentration, and executive functioning. He also re-
ports intermittent difficulty with comprehension of both
written and oral material, important word-finding prob-
lems. He has difficulty with elevated levels of anxiety,
depression, and anger. The patient is currently seeing a
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psychiatrist. His 47-year-old brother (Patient II-1) has pro-
found weakness and has much difficulty rising from the
floor and he has trouble rising from a chair. He has bilat-
eral cataracts. He complains of attention deficits and mem-
ory problems. He is currently taking medication for
generalized seizures that began at the age of 30. Neuroim-
aging scans are unavailable.
The same clinical criteria used to asses the presence of
cognitive and behavioral complaints in PROMM patients
were used for DM patients. Three patients (15%) had a
definite attitude of distrust and suspiciousness (Patients 9,
11, and 19) that fitted the criteria of a paranoid personal-
ity disorder, and two patients (Patients 14 and 10) had a
borderline personality disorder according to the DSM-IV
criteria.28 Recurrent, brief depressive disorders according
to DSM-IV28 have been found in two patients (Patients 6
and 18). In three patients (Patients 1, 2, and 4) there were
multiple cognitive deficits, including memory impairment
and difficulty in executive functioning, that were severe
enough to cause impairment in occupational and social
functioning so that a diagnosis of dementia was made ac-
cording to the DSM-IV criteria.28 Excessive daytime sleep-
iness was a subjective complaint in 16 of 20 patients, but
only in threee of these patients was it severe enough to
interfere with everyday activity.
Neuropsychological tests. The intergroup comparison
(table 3) indicates that patients with DM have generally
lower scores than age- and education-matched control sub-
jects. Patients with PROMM performed, in general, at an
intermediate level between DM and control subjects. Sig-
nificant differences were found for four tests: MMSE, story
recall, and copy and recall of Rey’s figure. A post hoc anal-
ysis using Scheffe’s method showed that patients with DM
performed at a significantly lower level than control sub-
jects ( p , 0.05) on MMSE, story recall, and Rey copy. In
the case of Rey recall, both patients with PROMM and DM
were impaired compared with control subjects.
In regard to normative data, approximately two-thirds
(64%) of the patients with PROMM and one-half (53%) of
those with DM showed an impairment of visual–spatial
recall (Rey recall), whereas only one-third of the patients
with PROMM (36%) and less than half of the DM patients
(47%) showed an impairment in visual–spatial construc-
tion (Rey copy). An impairment of verbal short-term and
long-term memory was significantly more common in pa-
tients with DM than in patients with PROMM (61% of
patients with DM versus 18% of patients with PROMM: x2
5 5.09; p . 0.005 in the story recall test; and 28% of
patients with DM failed in the digit span test whereas all
patients with PROMM performed correctly on this test: x2
5 4.0; p . 0.005). Considering the number of scores below
the age- and education-corrected cutoff value for each
pathologic group (PROMM and DM) on our battery of neu-
ropsychological tests, the overall neuropsychological per-
formance of impaired tests was 16 of 125 in the PROMM
group versus 55 of 214 impaired tests in the DM group
(x2 5 7.93; p . 0.005). The incidence of more pronounced
neuropsychological impairment, as measured by abnormal
performance in more than two tests, was higher in DM
patients than in PROMM patients (2 of 12 PROMM pa-
tients and 9 of 18 DM patients; approaching statistical
significance, x2 5 3.44, p 5 0.06). In the DM group, the
average age of the patients showing impairment in testing
was significantly higher (Mann–Whitney U test, z 5
22.65, p 5 0.008).
Magnetic resonance imaging. Figures 1 and 2 show the
scores of the grading used to assess GCA, FCA, and
WMHL for both PROMM (see figure 1) and DM (see figure
2) patients. The results have been compared with 20 con-
trol subjects whose brain MR images showed no GCA,
FCA, or WMHL (see tables 1 and 2).
Nine of the 17 patients with PROMM who underwent
MRI evaluations had normal results (see table 1). There
was no correlation between symptoms of brain disease and
the alterations observed in neuropsychological testing, or
with degree of neuromuscular involvement or age (see
table 1).
Of the DM patients undergoing MRI (n 5 15), five had
normal MRI results (see table 2). Of the remaining pa-
tients there was a more widespread distribution of the
focal hyperintense lesions compared with the distribution
of these lesions in patients with PROMM. However, as in
the PROMM patients, our results show no correlation be-
tween abnormalities of brain function on neuropsychologi-
cal testing and the degree of neuromuscular involvement
or the age of the patients (see table 2).
Positron emission tomography. In both the PROMM
and the DM patients there was a marked decrease in rCBF
in the frontal lobes bilaterally. In the PROMM patients
reductions in rCBF occurred bilaterally in the orbitofrontal
and the medial frontal cortex. The group analysis showed a
greater decrease in patients with DM. In the DM patients
there was not only a bilateral decrease in rCBF in the
orbitofrontal and medial frontal cortex, and in the tempo-
Table 3 Mean demographic variables and neuropsychological test
scores for myotonic dystrophy (DM) and proximal myotonic
myopathy (PROMM) patients compared with 20 controls
Variable
Patients
PROMM DM
Control
subjects p Value
Age, y 50.4 38.7 41.3 NS
Education, y 9.2 8.7 9.8 NS
MMSE score 28.8 27.9 29.6 0.003
Raven PMC score 29.6 26.7 30.4 NS
Token test score 34.4 35.4 35.6 NS
Weigl’s test score 10.4 9.9 12.7 NS
Controlled association
letters, score
33.1 25.8 34.1 NS
Controlled association
categories, score
37.4 37.9 41.3 NS
Story recall score 11.9 9.4 14.0 0.004
Digit span score 5.4 4.8 5.3 NS
Corsi span score 4.7 4.8 5.2 NS
Corsi supraspan score 24.0 15.4 21.9 NS
Rey copy score 29.7 25.9 35.2 0.001
Rey recall score 14.0 12.3 21.4 0.002
MMSE 5 Mini-Mental State Examination; PMC 5 progressive
matrices colored; NS 5 not significant.
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ral pole, but there was also a decrease in the dorsolateral
frontal cortex, the hypothalamus, and the left basal gan-
glia (figures 3 and 4).
Discussion. The results of neuropsychological
testing and PET in our patients with PROMM and
DM, as well as the findings of dementia and depres-
sion in 6 of 20 patients with PROMM, suggest that—
like DM—PROMM affects certain regions of the
brain. However, the limited number of patients
available requires caution in our interpretation of
the findings. We may have overestimated the fre-
quency of brain symptoms in PROMM due to a selec-
tion bias for patients having dementia and
depression. It is also possible that we may have stud-
ied a subset of patients with PROMM because
PROMM is probably a heterogeneous disorder.29
However, the patients in the current study from the
families with a family tree that permitted linkage
analysis showed no linkage to chromosomes 19q or
3q loci.
Although it is true that some neuropsychological
tests, like the copying of Rey’s figure, require motor
speed and coordination for normal performance, it
seems unlikely that the deficiencies in performance
that we observed in the patients with PROMM and
DM have resulted solely from their basic motor defi-
cits. None of the patients we have included in our
analysis have impaired motor and coordination abil-
ities sufficient to account for the results observed on
the cognitive testing (see tables 1 and 2). We have
taken care to disregard minor abnormalities in the
drawing pattern that could have resulted from motor
defects in our scoring procedure. It is also important
Figure 1. Brain MRI in patients with
proximal myotonic myopathy. See table 1
for clinical and laboratory details on
each patient. (A) Family 1, Patient V-2.
General cerebral atrophy (GCA), 1; focal
cerebral atrophy (FCA), 0; white matter
hyperintense lesions (WMHL), 0. Note
increased thecal thickness (arrows). (B)
Family 1, Patient III-8. GCA, 1; FCA, 2;
temporal lobe cyst; WMHL, 0. (C) Family
1, Patient III-1. GCA, 1; FCA, 0; WMHL,
0. (D) Family 1, Patient III-7. GCA, 0;
FCA, 0; WMHL, 1 (arrows). (E): Family
4, Patient II-1. GCA, 2; FCA, 0; WMHL,
1. (F) Family 3, Patient II-1. GCA, 0;
FCA, 0; WMHL, 1 (arrows).
Figure 2. Brain MRI in patients with myo-
tonic dystrophy. Grading is as in figure 1.
See table 2 for clinical and laboratory de-
tails on each patient. (A) A 35-year-old
man. General cerebral atrophy (GCA), 0;
focal cerebral atrophy (FCA), 0; white mat-
ter hyperintense lesions (WMHL), 1 (ar-
rows). (B) A 68-year-old woman. GCA, 2
(arrows); FCA, 0; WMHL, 0. (C) A 62-year-
old man. GCA, 2; FCA, 0; WMHL, 1. (D) A
40-year-old woman. GCA, 0; FCA, 0;
WMHL, 2. (E) A 36-year-old man. GCA, 1
(arrow); FCA, 2 (frontal lobe cyst); WMHL,
0. (F) A 53-year-old woman. GCA, 0; FCA,
1; WMHL, 2.
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to emphasize that some of our patients had scores in
the normal range on copying and showed impair-
ment only in recall.
The limited total number of PROMM and DM
patients with marked impairment has prevented a
detailed evaluation of the effects of age. Neuropsy-
chological impairment, in both PROMM and DM,
was more frequent in the older age group, suggest-
ing that there may be a gradual decline in certain
areas of cognitive function.
The nonspecific structural abnormalities observed
on brain MR images performed in both PROMM and
DM patients do not correlate clearly with the alter-
ations that we have observed on cognitive testing.
Conversely, functional neuroimaging with PET has
demonstrated a common pattern of cerebral hypoper-
fusion in both groups, with rCBF reductions in the
ventral and mesial aspects of the frontal lobes (or-
bitofrontal cortex) and in the temporal poles. Unfor-
tunately our current battery of neuropsychological
tests has not included some of the classic measure-
ments of frontal lobe function, such as the Wisconsin
Card Sorting Test or the Stroop interference task, so
that a correlation between rCBF frontal abnormali-
ties and impaired visual–spatial responses is limited.
It is, however, interesting to consider that the orbito-
frontal cortex and the temporal poles are intercon-
nected areas of brain, which can constitute a crucial
network for the control of emotional behavior.30,31 Be-
havioral and affective changes, such as depression,
apathy, or anxiety, are present in some of our pa-
tients with PROMM and DM. It is conceivable that
the alterations in CBF that we have observed in the
frontal lobes may contribute in part to producing the
disturbance in behavior seen in these patients with
PROMM and DM.
Previous PET studies in DM32,33 have suggested
that there may be a primary abnormality of the
carrier-mediated transport that accounts for the de-
cline of glucose utilization measured by 18F-labeled
Figure 3. Three-dimensional brain render-
ing (by statistical parametric mapping
[SPM-96]) demonstrating the areas of hypo-
perfusion in patients with proximal myo-
tonic myopathy compared with the control
group ( p , 0.001; z 5 3.09, corrected for
multiple comparisons).
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2-fluoro-2-deoxy-D-glucose (FDG) PET. These obser-
vations raise the possibility that the reduction in
cerebral glucose metabolism observed in DM may be
due to an alteration, such as a defect in membrane
function (carrier-mediated transport). Indeed, both
PROMM and DM are multisystem disorders and
may have multisystem alterations in membrane
function. Common pathophysiology seems likely to
exist for PROMM and DM. It is possible that this
abnormality may involve the insulin receptor. Pre-
liminary data in PROMM and DM have demon-
strated insulin resistance during euglycemic insulin
infusion studies (Moxley, unpublished data) and dur-
ing an intravenous glucose tolerance test.34 In the
future it would be helpful to perform PET/FDG stud-
ies on glucose kinetics in patients with PROMM and
DM to determine whether there is a relationship
between peripheral insulin resistance, which is com-
mon in these disorders, and the alterations in brain
function and CBF.
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